Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, is focused on the discovery, development, and commercialization of first-in-class glaucoma therapies. Its lead product candidate, Rhopressa, is a once-daily triple-action eye drop, which demonstrated the ability to reduce intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension in a Phase 2b clinical trial. The company is conducting two Phase 3 registration trials in the U.S. to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol, as well as commencing a third safety-only Phase 3 registration trial of Rhopressa in Canada. It also develops once-daily quadruple-action Roclatan, a single drop combination of Rhopressa with latanoprost, which has completed a 28-day Phase 2b clinical trial. In addition, the company is taking preparatory steps for Phase 3 registration trials for Roclatan. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Bedminster, New Jersey.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-3.31||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-15.12|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-30.07%||ROE||-120.74%||ROI|
|Current Ratio||7.63||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.46|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||35.07 M||Cash From Investing Activities||6.1 M||Cash From Operating Activities||-13.31 M||Gross Profit|
|Net Profit||-17.24 M||Operating Profit||-19.64 M||Total Assets||195.2 M||Total Current Assets||170.96 M|
|Total Current Liabilities||22.39 M||Total Debt||124.19 M||Total Liabilities||146.58 M||Total Revenue|
|High 52 week||60.04||Low 52 week||17.72||Last close||20.28||Last change||2.92%|
|RSI||39.39||Average true range||1.47||Beta||1.33||Volume||623.98 K|
|Simple moving average 20 days||-0.53%||Simple moving average 50 days||-6.05%||Simple moving average 200 days||-40.58%|
|Performance Week||8.28%||Performance Month||-14.93%||Performance Quart||-15.57%||Performance Half||-51.94%|
|Performance Year||-63.37%||Performance Year-to-date||-43.82%||Volatility daily||4.76%||Volatility weekly||10.64%|
|Volatility monthly||21.81%||Volatility yearly||75.54%||Relative Volume||235.1%||Average Volume||1.26 M|
|New High||New Low|
2020-06-05 11:31:03 | Aerie AERI Up 1.9% Since Last Earnings Report: Can It Continue?
2020-05-11 19:15:53 | Was The Smart Money Right About Aerie Pharmaceuticals Inc AERI?
2020-05-07 18:30:31 | Aerie Pharmaceuticals Inc AERI Q1 2020 Earnings Call Transcript
2020-05-07 16:11:49 | Edited Transcript of AERI earnings conference call or presentation 6-May-20 9:00pm GMT
2020-05-06 17:15:09 | Aerie Pharmaceuticals AERI Reports Q1 Loss, Lags Revenue Estimates
2020-05-06 15:00:00 | Aerie Pharmaceuticals, Inc. to Host Earnings Call
2020-04-28 12:34:04 | Aerie Pharmaceuticals AERI Expected to Beat Earnings Estimates: Should You Buy?
2020-04-13 10:01:02 | Aerie AERI Suspends Guidance Due to Coronavirus Outbreak
2020-04-09 16:01:00 | Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19
2020-04-07 07:30:00 | Aerie Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
2020-04-02 14:54:00 | Gone: Triangle public companies lose $30 billion in value during 1Q 2020
2020-03-25 10:18:19 | Healthcare Pro James Flynn Picks up These 3 Stocks on the Cheap
2020-03-21 11:30:03 | Why Is Aerie AERI Down 40.5% Since Last Earnings Report?
2020-02-24 07:30:00 | Aerie Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference
2020-02-21 19:39:40 | Edited Transcript of AERI earnings conference call or presentation 20-Feb-20 10:00pm GMT
2020-02-21 11:30:04 | Aerie's AERI Q4 Loss Wider Than Expected, Revenues Beat
2020-02-20 17:35:10 | Aerie Pharmaceuticals AERI Reports Q4 Loss, Tops Revenue Estimates
2020-02-20 10:50:48 | Some Market Stats In 5 Minutes
2020-02-12 05:13:05 | Aerie Pharmaceuticals, Inc.'s NASDAQ:AERI Path To Profitability
2020-01-21 06:30:00 | Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rocklatan® netarsudil and latanoprost ophthalmic solution 0.02%/0.005%
2020-01-07 05:26:16 | Does Aerie Pharmaceuticals NASDAQ:AERI Have A Healthy Balance Sheet?
2020-01-03 10:04:03 | Aerie's AERI Application for Roclanda Accepted in Europe
2019-12-09 06:30:00 | Aerie Pharmaceuticals Announces Appointment of Amine Sinmazisik as Director, Finance
2019-12-06 11:31:04 | Aerie AERI Up 4.7% Since Last Earnings Report: Can It Continue?
2019-12-04 09:19:44 | Is Aerie Pharmaceuticals Inc AERI A Good Stock To Buy ?
2019-12-02 04:56:18 | Did Aerie Pharmaceuticals, Inc. NASDAQ:AERI Insiders Buy Up More Shares?
2019-11-27 09:45:31 | 5 “Strong Buy” Biotech Stocks With More Than 80% Upside
2019-11-26 06:30:00 | Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference
2019-11-19 10:58:27 | Aerie buys Spanish outfit as it moves toward profitability
2019-11-19 09:31:02 | Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex
2019-11-12 07:30:00 | Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference
2019-11-07 10:51:03 | Aerie AERI Q3 Loss Wider, Sales Beat, Guidance Slashed